Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Investments (2020 - 2024)

Historic Long-Term Investments for Editas Medicine (EDIT) over the last 5 years, with Q2 2024 value amounting to $39.2 million.

  • Editas Medicine's Long-Term Investments fell 1850.31% to $39.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $39.2 million, marking a year-over-year decrease of 1850.31%. This contributed to the annual value of $104.0 million for FY2023, which is 1173.72% up from last year.
  • Latest data reveals that Editas Medicine reported Long-Term Investments of $39.2 million as of Q2 2024, which was down 1850.31% from $80.6 million recorded in Q1 2024.
  • Over the past 5 years, Editas Medicine's Long-Term Investments peaked at $120.1 million during Q4 2021, and registered a low of $39.2 million during Q2 2024.
  • Its 5-year average for Long-Term Investments is $82.3 million, with a median of $85.5 million in 2021.
  • In the last 5 years, Editas Medicine's Long-Term Investments surged by 11565.22% in 2021 and then plummeted by 4068.15% in 2022.
  • Quarter analysis of 5 years shows Editas Medicine's Long-Term Investments stood at $109.7 million in 2020, then increased by 9.49% to $120.1 million in 2021, then dropped by 22.47% to $93.1 million in 2022, then rose by 11.74% to $104.0 million in 2023, then crashed by 62.32% to $39.2 million in 2024.
  • Its Long-Term Investments was $39.2 million in Q2 2024, compared to $80.6 million in Q1 2024 and $104.0 million in Q4 2023.